| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Piclamilast manufacturers
- Piclamilast
-
- $44.00
-
2026-07-14
- CAS:144035-83-6
- Purity: 99.57%
- Supply Ability: 10g
|
| | Piclamilast Basic information |
| | Piclamilast Chemical Properties |
| Boiling point | 447.8±45.0 °C(Predicted) | | density | 1.370 | | storage temp. | 2-8°C | | solubility | DMSO: soluble20mg/mL, clear | | pka | 10.10±0.70(Predicted) | | form | powder | | color | white to beige | | InChI | 1S/C18H18Cl2N2O3/c1-24-15-7-6-11(8-16(15)25-12-4-2-3-5-12)18(23)22-17-13(19)9-21-10-14(17)20/h6-10,12H,2-5H2,1H3,(H,21,22,23) | | InChIKey | RRRUXBQSQLKHEL-UHFFFAOYSA-N | | SMILES | Clc1cncc(c1NC(=O)c2cc(c(cc2)OC)OC3CCCC3)Cl |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | Piclamilast Usage And Synthesis |
| Uses | Piclamilast is a potent and selective phosphodiesterase-4 (PDE4) inhibitor. Piclamilast may offer therapeutic strategies in respiratory diseases, including asthma and chronic obstructive pulmonary disease. Piclamilast may also provide a treatment option for pre-term infants with bronchopulmonary dysplasia (BPD). | | Definition | ChEBI: A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine. | | Biological Activity | Piclamilast is a potent and selective cyclic AMP phosphodiesterase-4 inhibitor th at exhibits equal, high affinity for both the PDE4 high- and low-affinity rolipram binding states (HARBS and LARBS). Recent studies shown th at piclamilast inhibits Trypanosoma brucei PDEB1 (TbrPDEB1) and TbrPDEB2.', 'Piclamilast is also known as N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide. Piclamilast regulates the cAMP (cyclic adenosine monophosphate) signaling pathway. It increases the retinoid-dependent transactivation and the degradation of retinoic acid receptor α (RARα). | | in vivo | Piclamilast (RP 73401, 10 mg/kg, 30 min) alone does not affect the MST of leukemia-bearing animals. Piclamilast combined with ATRA (HY-14649) significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals[3]. | Animal Model: | SCID mice[3]. | | Dosage: | 10 mg/kg (combined with ATRA (HY-14649)). | | Administration: | Injection daily. | | Result: | Significantly more effective than ATRA alone in increasing the MST (40 days; interval 34–45 days) of leukemia-bearing animals. |
| | IC 50 | PDE4: 16 nM (IC50, in pig aorta); PDE4: 2 nM (IC50, in eosinophil soluble); PDE1: >100 μM (IC50); PDE2: 40 μM (IC50); PDE3: >100 μM (IC50); PDE5: 14 μM (IC50) | | storage | Store at RT |
| | Piclamilast Preparation Products And Raw materials |
|